SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:0028 3878 ;pers:(Svenningsson Anders)"

Sökning: L773:0028 3878 > Svenningsson Anders

  • Resultat 1-8 av 8
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Bergman, Joakim, et al. (författare)
  • Intrathecal treatment trial of rituximab in progressive MS: An open-label phase 1b study
  • 2018
  • Ingår i: Neurology. - : Wolters Kluwer. - 1526-632X .- 0028-3878. ; 91:20
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVES: To perform a phase 1b assessment of the safety and feasibility of intrathecally delivered rituximab as a treatment for progressive multiple sclerosis (PMS) and to evaluate the effect of treatment on disability and CSF biomarkers during a 1-year follow-up period. METHODS: Three doses of rituximab (25 mg with a 1-week interval) were administered in 23 patients with PMS via a ventricular catheter inserted into the right frontal horn and connected to a subcutaneous Ommaya reservoir. Follow-ups were performed at 1, 3, 6, 9, and 12 months. RESULTS: Mild to moderate vertigo and nausea were common but temporary adverse events associated with intrathecal rituximab infusion, which was otherwise well tolerated. The only severe adverse event was a case of low-virulent bacterial meningitis that was treated effectively. Of 7 clinical assessments, only 1 showed statistically significant improvement 1 year after treatment. No treatment effect was observed during the follow-up period among 6 CSF biomarkers. CONCLUSIONS: Intrathecal administration of rituximab was well tolerated. However, it may involve a risk for injection-related infections. The lack of a control group precludes conclusions being drawn regarding treatment efficacy. CLINICALTRIALSGOV IDENTIFIER: NCT01719159. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that intrathecal rituximab treatment is well tolerated and feasible in PMS but involves a risk of severe infections. © 2018 American Academy of Neurology.
  •  
2.
  • de Flon, Pierre, et al. (författare)
  • Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab
  • 2016
  • Ingår i: Neurology. - Philadelphia, USA : Lippincott Williams & Wilkins. - 0028-3878 .- 1526-632X. ; 87:2, s. 141-147
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective: To describe the effects of switching treatment from ongoing first-line injectable therapies to rituximab on inflammatory activity measured by MRI and levels of CSF neurofilament light chain (CSF-NFL) in a cohort of patients with clinically stable relapsing-remitting multiple sclerosis (RRMS).Method: Seventy-five patients with clinically stable RRMS treated with the first-line injectables interferon-β (IFN-β) and glatiramer acetate (GA) at 3 Swedish centers were switched to rituximab in this open-label phase II multicenter study. After a run-in period of 3 months, 2 IV doses of 1,000 mg rituximab were given 2 weeks apart followed by repeated clinical assessment, MRI, and CSF-NFL for 24 months.Results: The mean cumulated number of gadolinium-enhancing lesions per patient at months 3 and 6 after treatment shift to rituximab was reduced compared to the run-in period (0.028 vs 0.36, p = 0.029). During the first year after treatment shift, the mean number of new or enlarged T2 lesions per patient was reduced (0.01 vs 0.28, p = 0.004) and mean CSF-NFL levels were reduced by 21% (p = 0.01).Conclusions: For patients with RRMS, a treatment switch from IFN or GA to rituximab is associated with reduced inflammatory activity measured by MRI and CSF-NFL.Classification of evidence: This study provides Class IV evidence that rituximab has an equal or superior effect in reducing inflammatory activity in RRMS measured by MRI and CSF-NFL compared to first-line injectables during the first year after treatment shift.
  •  
3.
  •  
4.
  • Novakova, Lenka, 1984, et al. (författare)
  • Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.
  • 2017
  • Ingår i: Neurology. - : Lippincott Williams & Wilkins. - 1526-632X .- 0028-3878. ; 89:22, s. 2230-2237
  • Tidskriftsartikel (refereegranskat)abstract
    • To examine the effects of disease activity, disability, and disease-modifying therapies (DMTs) on serum neurofilament light (NFL) and the correlation between NFL concentrations in serum and CSF in multiple sclerosis (MS).NFL concentrations were measured in paired serum and CSF samples (n = 521) from 373 participants: 286 had MS, 45 had other neurologic conditions, and 42 were healthy controls (HCs). In 138 patients with MS, the serum and CSF samples were obtained before and after DMT treatment with a median interval of 12 months. The CSF NFL concentration was measured with the UmanDiagnostics NF-light enzyme-linked immunosorbent assay. The serum NFL concentration was measured with an in-house ultrasensitive single-molecule array assay.In MS, the correlation between serum and CSF NFL was r = 0.62 (p < 0.001). Serum concentrations were significantly higher in patients with relapsing-remitting MS (16.9 ng/L) and in patients with progressive MS (23 ng/L) than in HCs (10.5 ng/L, p < 0.001 and p < 0.001, respectively). Treatment with DMT reduced median serum NFL levels from 18.6 (interquartile range [IQR] 12.6-32.7) ng/L to 15.7 (IQR 9.6-22.7) ng/L (p < 0.001). Patients with relapse or with radiologic activity had significantly higher serum NFL levels than those in remission (p < 0.001) or those without new lesions on MRI (p < 0.001).Serum and CSF NFL levels were highly correlated, indicating that blood sampling can replace CSF taps for this particular marker. Disease activity and DMT had similar effects on serum and CSF NFL concentrations. Repeated NFL determinations in peripheral blood for detecting axonal damage may represent new possibilities in MS monitoring.
  •  
5.
  • Salzer, Jonatan, et al. (författare)
  • Rituximab in multiple sclerosis : a retrospective observational study on safety and efficacy
  • 2016
  • Ingår i: Neurology. - 0028-3878 .- 1526-632X. ; 87:20, s. 2074-2081
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective: To investigate the safety and efficacy of rituximab in multiple sclerosis (MS). Methods: In this retrospective uncontrolled observational multicenter study, off-label rituximab-treated patients with MS were identified through the Swedish MS register. Outcome data were collected from the MS register and medical charts. Adverse events (AEs) grades 2-5 according to the Common Terminology Criteria for Adverse Events were recorded. Results: A total of 822 rituximab-treated patients with MS were identified: 557 relapsing-remitting MS (RRMS), 198 secondary progressive MS (SPMS), and 67 primary progressive MS (PPMS). At baseline, 26.2% had contrast-enhancing lesions (CELs). Patients were treated with 500 or 1,000 mg rituximab IV every 6-12 months, during a mean 21.8 (SD 14.3) months. During treatment, the annualized relapse rates were 0.044 (RRMS), 0.038 (SPMS), and 0.015 (PPMS), and 4.6% of patients displayed CELs. Median Expanded Disability Status Scale remained unchanged in RRMS (p = 0.42) and increased by 0.5 and 1.0 in SPMS and PPMS, respectively (p = 0.10 and 0.25). Infusion-related AEs occurred during 7.8% of infusions and most were mild. A total of 89 AEs grades >= 2 (of which 76 infections) were recorded in 72 patients. No case of progressive multifocal leukoencephalopathy was detected. Conclusions: This is the largest cohort of patients with MS treated with rituximab reported so far. The safety, clinical, and MRI findings in this heterogeneous real-world cohort treated with different doses of rituximab were similar to those reported in previous randomized controlled trials on B-cell depletion therapy in MS. Classification of evidence: This study provides Class IV evidence that for patients with MS, rituximab is safe and effective.
  •  
6.
  •  
7.
  •  
8.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-8 av 8
Typ av publikation
tidskriftsartikel (8)
Typ av innehåll
refereegranskat (6)
övrigt vetenskapligt/konstnärligt (2)
Författare/redaktör
Sundström, Peter (5)
Zetterberg, Henrik, ... (2)
Gilthorpe, Jonathan ... (2)
Bergman, Joakim (2)
Piehl, Fredrik (2)
visa fler...
Gunnarsson, Martin, ... (2)
Salzer, Jonatan (2)
Vågberg, Mattias (2)
Blennow, Kaj, 1958 (1)
Rosengren, Lars, 195 ... (1)
Lycke, Jan, 1956 (1)
Khademi, Mohsen (1)
Olsson, Tomas (1)
Brännström, Thomas (1)
Axelsson, Markus, 19 ... (1)
Bergenheim, Tommy (1)
Gunnarsson, M (1)
Alping, Peter (1)
Fink, Katharina (1)
Fogdell-Hahn, Anna (1)
Burman, J. (1)
Novakova, Lenka, 198 ... (1)
Malmeström, Clas, 19 ... (1)
Lycke, Jan (1)
Islam-Jakobsson, Pro ... (1)
Krauss, Wolfgang, 19 ... (1)
Söderström, Lars (1)
Birgander, Richard (1)
Laurell, Katarina (1)
Axelsson, Markus (1)
Malmeström, Clas (1)
Stigbrand, Torgny (1)
Berko, Sara (1)
Dring, Ann (1)
Jiltsova, E. (1)
Norgren, Niklas (1)
Engdahl, Elin (1)
Lundkvist, Malin (1)
de Flon, Pierre (1)
Lindqvist, Thomas (1)
Falk, Eva (1)
Schreiber, Karen (1)
Jones, Iwan (1)
Penner, Iris-Kathari ... (1)
Fuchs, Siegrid (1)
Svenningsson, Rasmus (1)
Novakova, Lenka (1)
Björck, Anna (1)
Dring, Ann Marie (1)
visa färre...
Lärosäte
Umeå universitet (8)
Karolinska Institutet (5)
Göteborgs universitet (3)
Örebro universitet (2)
Uppsala universitet (1)
Språk
Engelska (8)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (8)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy